未登录.png)
分享.png)
收藏分享 收藏 Real-world evaluation of CDK4/6 inhibitors in hormone receptor-positive metastatic breast cancer: prognostic effect of proton pump inhibitor useCDK4/6抑制剂在激素受体阳性转移性乳腺癌中的真实世界评估：质子泵抑制剂使用的预后影响
Chen, Bo-Fang; Lai, Jiun-, I; Tsai, Yi-Fang; Lien, Pei-Ju; Lin, Yen-Shu; Feng, Chin-Jung; Chen, Yen-Jen; Cheng, Han-Fang; Chao, Ta-Chung; Liu, Chun-Yu; Tseng, Ling-Ming; Huang, Chi-Cheng 分享 收藏 分享 收藏 Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohortCapivasertib 联合 Fulvestrant 治疗HR阳性/HER2阴性晚期乳腺癌：CAPItello-291研究扩展的中国队列Hu, Xichun; Zhang, Qingyuan; Sun, Tao; Xiong, Huihua; Li, Wei; Teng, Yuee; Lu, Yen-Shen; Tseng, Ling-Ming; Yan, Min; Li, Hongsheng; Pang, Danmei; -Chen, Shin-Cheh; Chen, Wenyan; Jiang, Ou; Wang, Jingfen; Wu, Xinhong; Wang, Xian; Zang, Aimin; Wang, Xiaojia; Collins, Julie M.; Fan, Ethan; Jiang, Lin; Zeng, Xiaoling; Turner, Nicholas C. 分享 收藏 分享 收藏 Genetic Alterations in HER2-Positive and Equivocal Breast Cancer by Immunohistochemistry免疫组织化学在HER2-Positive和模棱两可的乳腺癌中的遗传改变Tsai, Yi-Fang; Hsu, Chih-Yi; Chiu, Yun-Ning; Huang, Chi-Cheng; Chou, Shih-Hsiang; Lin, Yen-Shu; Chao, Ta-Chung; Liu, Chun-Yu; Chiu, Jen-Hwey; Tseng, Ling-Ming 分享 收藏 分享 收藏 分享 收藏 Abemaciclib combined with endocrine therapy as adjuvant treatment for hormone-receptor-positive, HER2-, high-risk early breast cancer: 5-year Chinese population analysis of the phase III randomized monarchE studyAbemaciclib联合内分泌治疗作为激素受体阳性，HER2-高危早期乳腺癌的辅助治疗: III期随机monarchE研究的5年中国人群分析Zhang, Qingyuan; Shen, Kunwei; Song, Chuan-gui; Ouyang, Quchang; Liu, Zhenzhen; Liu, Qiang; Feng, Jifeng; Chiu, Joanne W. Y.; Tang, Jinhai; Jiang, Zefei; Tseng, Ling-Ming; Wang, Xiaojia; Yang, Liu; Qian, Chenxi; Shao, Zhimin 分享 收藏 Estimating the risk of major adverse cardiac events following radiotherapy for left breast cancer using a modified generalized Lyman normal-tissue complication probability modelLai, Tzu-Yu; Hu, Yu-Wen; Wang, Ti-Hao; Chen, Jui-Pin; Shiau, Cheng-Ying; Huang, Pin-, I; Lai, I. -Chun; Liu, Yu-Ming; Huang, Chi-Cheng; Tseng, Ling-Ming; Huang, Nicole; Liu, Chia-Jen 分享 收藏 A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancerNoguchi, Emi; Yamanaka, Takashi; Mukai, Hirofumi; Yamamoto, Naohito; Chung, Chi-Feng; Lu, Yen-Shen; Chang, Dwan-Ying; Sohn, Joohyuk; Kim, Gun Min; Lee, Kyung-Hun; Lee, Soo-Chin; Iwasa, Tsutomu; Iwata, Hiroji; Watanabe, Kenichi; Jung, Kyung Hae; Tanabe, Yuko; Kang, Seok Yun; Yasojima, Hiroyuki; Aogi, Kenjiro; Tokunaga, Eriko; Sim, Sung Hoon; Yap, Yoon Sim; Matsumoto, Koji; Tseng, Ling-Ming; Umeyama, Yoshiko; Sudo, Kazuki; Kojima, Yuki; Hata, Tomomi; Kuchiba, Aya; Shibata, Taro; Nakamura, Kenichi; Fujiwara, Yasuhiro; Tamura, Kenji; Yonemori, Kan 分享 收藏 Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trialIgnatiadis, Michail; Bailey, Andrew; McArthur, Heather; El-Abed, Sarra; de Azambuja, Evandro; Metzger, Otto; Chui, Steve; Dieterich, Max; Perretti, Thomas; Steger, Guenther; Jassem, Jacek; Lee, Soo Chin; Higgins, Michaela; Zarba, Jose; Schmidt, Marcus; Gomez, Henry; Guerrero-Zotano, Angel; Moscetti, Luca; Chiu, Joanne Win Yang; DuFrane, Carter; Honvault, Vanessa; Altarcheh, Rosa; Molinero, Luciana; Ellingson, Andrew; Munzone, Elisabetta; Ben-Baruch, Noa Efrat; Bajetta, Emilio; Ohno, Shinji; Im, Seock-Ah; Werutsky, Gustavo; Gal-Yam, Einav; Gonzalez-Farre, Xavier; Tseng, Ling-Ming; Jacot, William; Gluz, Oleg; Shao, Zhimin; Shparyk, Yaroslav; Sinielnikov, Ivan; Anastasia, Zimina; Vasiliev, Aleksandr; Shearer-Kang, Esther; Winer, Eric; Martins-Branco, Diogo; Fielding, Shona; Cameron, David; Viale, Giuseppe; Saji, Shigehira; Gelber, Richard; Piccart, Martine 分享 收藏 分享 收藏 Role of ITGB2 in patients with luminal B1 breast cancerLiu, Chun-Yu; Chen, Ji-Lin; Tsai, Yi-Fang; Chao, Ta-Chung; Wang, Wan-Lun; Lien, Pei-Ju; Hsu, Chih-Yi; Lai, Jiun-I; Huang, Chi-Cheng; Chiu, Jen-Hwey; Tseng, Ling-Ming 分享 收藏 Identification of CDK6 binding proteins by proximity labeling reveals novel mechanisms for CDK4/6 inhibitor resistance in breast cancerTing, Chung Wei; Zhuang, Yong-Ji; Lin, Chih-Yi; Yu, Chung-Jen; Chao, Ta-Chung; Tseng, Ling-Ming; Liu, Chun-Yu; Tsai, Yi-Fang; Huang, Chi-Cheng; Lai, Jiun-I 分享 收藏 分享 收藏 CDK7 modulation of Hippo-YAP activity by RNAPII phosphorylation regulates CDK4/6 inhibitor resistance in hormone positive breast cancerYu, Chung-Jen; Zhuang, Yong-Ji; Lin, Chih-Yi; Tseng, Yi-Ru; Lin, Ting-Yi; Shih, Hsiu-Man; Liu, Chun-Yu; Chao, Ta-Chung; Tseng, Ling-Ming; Huang, Chi-Cheng; Tsai, Yi-Fang; Tsai, Feng Chiao; Lai, Jiun-I 分享 收藏 分享 收藏 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
